Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting - Drugs.com MedNews
Links shared publicly online about this topic.
- 672total visits
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting - Drugs.com MedNews
CPX-351 produced higher remission rates, reduced early mortality, with improvements in event-free survival and overall survival in elderly patients with newly-d
View full resource at drugs.com
Tags: Drug, Pharma, Phase 2 Clinical Trial, Senior Health, Mortality
Most Recently Shared on December 7, 2010 at 2:12 pm By:
Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of He... http://bit.ly/dGWN9K #drug
Advertisement
